Cleared Dual Track

WELLlife COVID-19 Antigen Test Rx

K251289 · Guangzhou Wondfo Biotech Co., Ltd. · Microbiology

Oct 2025

Decision

180d

Days

Class 2

Risk

About This 510(k) Submission

K251289 is an FDA 510(k) clearance for the WELLlife COVID-19 Antigen Test Rx, a Simple Point-of-care Device To Directly Detect Sars-cov-2 Viral Targets From Clinical Specimens In Near-patient Settings (Class II — Special Controls, product code QVF), submitted by Guangzhou Wondfo Biotech Co., Ltd. (Guangzhou, CN). The FDA issued a Cleared decision on October 22, 2025, 180 days after receiving the submission on April 25, 2025. This device falls under the Microbiology review panel. Regulated under 21 CFR 866.3982.

Submission Details

510(k) Number	K251289 FDA.gov
FDA Decision	Cleared SESE
Date Received	April 25, 2025
Decision Date	October 22, 2025
Days to Decision	180 days
Submission Type	Dual Track
Review Panel	Microbiology (MI)
Summary	Summary PDF

Device Classification

Product Code	QVF — Simple Point-of-care Device To Directly Detect Sars-cov-2 Viral Targets From Clinical Specimens In Near-patient Settings
Device Class	Class II — Special Controls
CFR Regulation	21 CFR 866.3982
Definition	A Simple Point-of-care Device To Detect Sars-cov-2 Viral Targets Directly From Clinical Specimens In Near-patient Settings Is An In Vitro Diagnostic Device For The Direct Detection Of Sars-cov-2 In Clinical Specimens And Is Intended As An Aid In The Diagnosis Of Sars-cov-2 Infections Covid-19). The Device Is Simple To Use And Does Not Involve Sample Manipulation, Transportation Of The Sample To Another Functional Area (e.g., A Central Laboratory Or Other Specialized Area), Or Measurement Of Reagents Or Analytes That Could Be Affected By Conditions Such As Sample Turbidity Or Cell Lysis. The Design And Procedures Of The Device Are Appropriate For Use By Healthcare Professionals In Near-patient Settings Outside A Centralized Laboratory